Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now

bluebird bio, Inc.

1 day chart

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About BLUE

bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

Find out what a historical investment in bluebird bio, Inc. would be worth today using our BLUE stock calculator.

Market Capitalisation

$48.86M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

217.72K

High today

$4.99

Low today

$4.98

Open price

$4.99

52-week high

$28.60

52-week low

$3.20

Ready to start your investing journey with Stake?

Open an account

BLUE FAQs

Buying BLUE shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in bluebird bio, Inc. in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in BLUE

The ticker symbol for bluebird bio, Inc. is BLUE.

One share of BLUE is valued at $4.99 as of 24 May 2025.

As of 24 May 2025 bluebird bio, Inc. has a market cap of $48.86M.

The bluebird bio, Inc. 52-week high stock price is $28.60.

The bluebird bio, Inc. 52-week low stock price is $3.20.

Yes, the Stake investing platform allows you to buy BLUE shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in BLUE
on Stake

Buy BLUE from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of BLUE from only US$10 with fractional shares

Get started
Stake app chart
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
BLUE related stocks

Stake logo
Over 12,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2025 Stake. All rights reserved.